Related Experiment Video

Updated: Aug 11, 2026

Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

Role of osteoprotegerin (OPG) in cancer

Ingunn Holen1, Claire M Shipman

  • 1Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield S10 2RX, U.K. I.Holen@Sheffield.ac.uk

Clinical Science (London, England : 1979)
|February 9, 2006
PubMed

Insights

Osteoprotegerin (OPG) regulates bone turnover and inhibits osteoclast activity. This review explores OPG's role in cancer-induced bone disease, tumor growth, and survival.

Area of Science:

  • Oncology
  • Bone Biology
  • Immunology

Background:

  • Osteoprotegerin (OPG) is a secreted protein regulating bone turnover.
  • OPG inhibits osteoclastic bone resorption, showing therapeutic potential for osteoporosis and cancer-induced bone disease.
  • OPG also binds TNF-related apoptosis-inducing ligand (TRAIL), influencing tumor cell survival.

Purpose of the Study:

  • To review the multifaceted role of OPG in cancer.
  • To discuss OPG's involvement in cancer-induced bone disease.
  • To examine OPG's impact on tumor growth, survival, and its potential as a prognostic marker.

Main Methods:

  • Literature review of studies on OPG in cancer.
  • Analysis of in vitro and in vivo models investigating OPG's functions.
  • Examination of clinical data on OPG as a prognostic marker.

Main Results:

  • OPG inhibits osteoclastic bone resorption, reducing tumor burden in bone disease models.
  • In vitro studies suggest OPG protects tumor cells from TRAIL-induced apoptosis.
  • OPG shows potential as a prognostic marker in myeloma, breast, and prostate cancers.

Conclusions:

  • OPG plays a significant role in cancer-induced bone disease.
  • OPG may promote tumor cell survival, though in vivo validation is needed.
  • OPG's prognostic value in various cancers warrants further investigation.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...